Peer-reviewedCC BY 4.0Frontiers in Immunology
Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
5 affiliations
- 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele
- 2Medical Oncology Department, Humanitas Istituto Clinico Catanese, Misterbianco
- 3Department of Internal Medicine, Division of Medical Oncology, The Arthur G. James Comprehensive Cancer Center
- 4Division of Medical Oncology, “Gaetano Martino” Hospital
- 5Department of Human Pathology “G. Barresi”, University of Messina
Related
- Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer
- Immune-checkpoint blockade and candidate predictive biomarkers in HIV-negative Kaposi sarcoma: current evidence and a practical research framework
- Galectin-3 and TREM2: a myeloid axis as a predictive biomarker for immune checkpoint inhibitors in cancer
- Evidence for Dose Optimization of Immune Checkpoint Inhibitors.
- Rechallenge After Immune Checkpoint Inhibitors Myocarditis: Evidence and a Practical Framework
BibTeX
@article{russo2026editorial,
title = {{Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer}},
author = {Alessandro Russo and Christian Rolfo and Mariacarmela Santarpia},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.2011872},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.2011872/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Editorial: Predictive biomarkers to immune checkpoint inhibitors in lung cancer
AU - Alessandro Russo
AU - Christian Rolfo
AU - Mariacarmela Santarpia
PY - 2026
DA - 2026/10/20
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.2011872
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.2011872/full
SN - 1664-3224
ER -